*Yuka MORIYA1, Akihiro MOURI2,5, Mai MIYACHI1, Hitomi KURAHASHI2, Takemi Fuwa2, Takaya NISHIKAWA2, Toshitaka NABESHIMA3,5, Kuniaki SAITO4,5, Yoichi HASEGAWA1
(1. Faculty of Pharmacy, Meijo University, Japan, 2. Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Japan, 3. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Science, Japan, 4. Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Japan, 5. Japanese Drug Organization of Appropriate Use and Research, Japan)
Keywords:Autism spectrum disorder
Abstract password authentication.
A password is required to view the full text of the abstract. Please enter the following password.
PW: Neuro2022